secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001493152-24-031471
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed Q2 GAAP net loss $10.9M; Lucid EsoGuard test volume record 3,147 (up 31% QoQ)
--------------------------------------------------------------------------------

- Q2 revenue $1.0M from EsoGuard test; GAAP net loss attributable to common $10.9M ($1.19/sh).
- Adjusted non-GAAP loss $7.7M ($0.84/sh). Cash and equivalents $25.5M at June 30, 2024.
- Lucid commercial EsoGuard tests: 3,147 in Q2 (single-quarter record), +31% sequential, +44% YoY.
- Lucid held productive meeting with CMS MAC Palmetto GBA's MolDX program for EsoGuard coverage.
- Veris launched pilot with Ohio State's James Cancer Hospital; actively pursuing independent financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315224031471/0001493152-24-031471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315224031471/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer